Skip to main content
Welcome to
Sanofi in India
  • About us
  • Our presence
  • Investors
    • Investors
    • Our Business
    • Board of Directors and Leadership Team
      • Board of Directors and Leadership Team
      • Board of Directors
      • Board Committees
      • Leadership Team
    • Financial Results
    • Annual Reports
    • AGM
    • Scheme of Arrangement
    • Investor Information
      • Investor Information
      • Shareholding Pattern
      • Corporate Governance
      • Analyst / Investor Meet
      • Postal Ballot
      • Secretarial Compliance Report
      • Related Party Disclosures
      • Annual Return
      • Stock Exchange Announcement And Disclosures
      • Newspaper Advertisement
    • Disclosures Under Reg. 46 of the Listing Regulations
      • Disclosures Under Reg. 46 of the Listing Regulations
      • Our Business
      • Letter of Appointment of Independent Directors
      • Composition of Board Committee
      • Code of Conduct and Policies
      • Familiarization Programme
      • Contact information for grievance redressal
      • Notice of Board Meeting
      • Financial results
      • Annual Report
      • Shareholding Pattern
      • Analyst Meet
      • Notice given to shareholders by way advertisement
      • Credit Rating
      • Audited financial results of Subsidiary
      • Secretarial Compliance Report
      • Policy for determination of materiality for disclosure of event or information
      • Contact details for the Key Managerial Personnel authorized for determining materiality of an event or information as per Reg. 30 of SEBI LODR
      • Disclosures under Reg. 30 of the Listing Regulations
      • Annual Return
    • CSR
    • Shareholder’s Corner
      • Shareholder’s Corner
      • Unclaimed dividends
      • Unclaimed shares
      • Investor services
      • Contact Us
  • Careers
  • Home Page
  • Investors
  • Disclosures Under Reg. 46 of the Listing Regulations
  • Disclosures under Reg. 30 of the Listing Regulations

Disclosures under Reg. 30 of the Listing Regulations

    Disclosures under Reg. 30 of the Listing Regulations 2023

    • PDF • September 2023
      Observation letters from BSE and NSE for the Scheme of Demerger
    • PDF • September 2023
      Change in Sr. Management
    • PDF • August 2023
      Reg 30 – Pending Litigation
    • PDF • August 2023
      Change in Sr. Management
    • PDF • June 2023
      Resignation of Director
    • Video • May 2023
      Recording of Investor / Analyst Call - May 2023
    • PDF • May 2023
      Presentation of Investor/Analyst call May 2023
    • PDF • May 2023
      Reg 30 Scheme of arrangement
    • PDF • May 2023
      Intimation for Investor / Analysts Call – May 2023
    • PDF • April 2023
      Announcement Under Regulation 30 - NLEM Communication
    • PDF • Feb 2023
      Investor / Analyst Meet Transcript 24.02.2023
    • PDF • 2023-02-24
      Presentation for Investor / Analyst call – Feb 2023
    • PDF • 2023-02-16
      Intimation for Investor / Analysts Call

    Disclosures under Reg. 30 of the Listing Regulations 2022

    • PDF • 2022-03-11
      Announcement under Regulation 30 (LODR)-Change in Directorate
    • PDF • 2022-09-16
      Reg 30 anouncement - NSE BSE NLEM
    • PDF • 2022-06-01
      Authorized officials for disclosure of Material information to Stock Exchange
    • PDF • 2022-02-23
      Intimation for Investor Call
    • PDF • 2022-01-13
      Resignation of Managing Director

    Disclosures under Reg. 30 of the Listing Regulations 2021

    • PDF • November 26, 2021
      Divestment of Soframycin® and Sofradex® businesses
    • PDF • November 24, 2021
      Resignation of Non-Executive Director
    • PDF • October 27, 2021
      Appointment of Company Secretary and change in Compliance Officer
    • PDF • August 13, 2021
      Resignation of Company Secretary (Key Managerial Personnel) & Change in Compliance Officer
    • PDF • July 28, 2021
      Slump Sale and transfer of the Nutraceuticals business of the Company
    • PDF • March 17, 2021
      Investor Webinar Presentation - 17th March 2021
    • PDF • February 24, 2021
      Intimation for Investor Webinar on 17th March 2021
    • PDF • February 24, 2021
      Appointment / Re-appointment of Directors, Re-appointment of Chairman

    Disclosures under Reg. 30 of the Listing Regulations 2020

    • PDF • October 06, 2020
      Authorized officials for disclosure of material information to Stock Exchanges
    • PDF • October 05, 2020
      Appointment of Chief Financial Officer
    • PDF • September 16, 2020
      Resignation of Whole Time Director & Chief Financial Officer
    • PDF • July 28, 2020
      Disclosure on Impact of COVID-19

    Disclosures under Reg. 30 of the Listing Regulations 2019

    • PDF • September 11, 2019
      Outcome of Board Meeting held on 10th September 2019
    • PDF • May 7, 2019
      Resignation of Whole Time Director
    • PDF • February 19, 2019
      Clarification on the media report in ‘The Hindu’

    Disclosures under Reg. 30 of the Listing Regulations 2018

    • PDF • November 13, 2018
      Clarification on the media report in the Indian Express
    • PDF • May 09, 2018
      Change in Chief Financial Officer

    Disclosures under Reg. 30 of the Listing Regulations 2015

    • PDF • 2016-01-12
      Disclosure under Regulation 30(5) of LODR 2015 - 10.12.2015
Home Page - Sanofi India | go to homepage
  • Contact Us
  • Legal Notice
  • Sitemap

 

© Sanofi 2006-2022 - All rights reserved

You are about to leave sanofiindialtd.com website

By clicking on Proceed, you will be redirected to External Website.

Do you wish to Proceed ?

PROCEED